ISSN (Print) - 0012-9976 | ISSN (Online) - 2349-8846

A+| A| A-

Madhusudan Industries

Continued Expansion GLINDIA is again changing its name and will be called 'Glaxo India'. The company continues to increase its manufacturing facilities. It incurred an expenditure of Rs 16.37 crore on the creation of facilities for the manufacture of the bulk drugs Ranitidine, Cephalexin and Griseofulvin at Ankleshwar, Ranitidine formulations at Nashik and also on the continuing modernisation of manufacturing operations at other factories, including the foods factory at Aligarh.

Dear reader,

To continue reading, become a subscriber.

Explore our attractive subscription offers.

Click here

Comments

(-) Hide

EPW looks forward to your comments. Please note that comments are moderated as per our comments policy. They may take some time to appear. A comment, if suitable, may be selected for publication in the Letters pages of EPW.

Back to Top